Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Anticancer Research

• Publication date

  2005-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 16080489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Prognostic Value of the Mitotic Activity Index in Patients with Primary Breast Cancer Who were not Treated with Adjuvant Systemic Therapy

  2004cited by this paper
• Do younger female breast cancer patients have a poorer prognosis? Results from a population‐based survival analysis

  2004cited by this paper
• Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment

  2004cited by this paper
• Breast cancer in young women: clinicopathological features and biological specificity.

  2003cited by this paper
• Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer.

  2003cited by this paper
• Do we need HER‐2/neu testing for all patients with primary breast carcinoma?

  2003cited by this paper
• Is invasive lobular carcinoma different from invasive ductal carcinoma?

  2003cited by this paper
• Incidence and prognosis in early onset breast cancer.

  2002cited by this paper
• Quantitation of erbB2 positivity for evaluation of high-risk patients

  2002cited by this paper
• Young age as an adverse prognostic factor in premenopausal women with operable breast cancer.

  2002cited by this paper
• Prognostication of invasive ductal breast cancer by quantification of E‐cadherin immunostaining: themethodology and clinical relevance

  2002cited by this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF HORMONE RECEPTORS IN INVASIVE BREAST CARCINOMA: CORRELATION OF RESULTS OF H‐SCORE WITH PATHOLOGICAL PARAMETERS

  2001cited by this paper
• p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

  2000cited by this paper
• Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients.

  2000cited by this paper
• Quantitative image analysis of estrogen and progesterone receptors as a prognostic tool for selecting breast cancer patients for therapy.

  1999cited by this paper
• Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

  1999cited by this paper
• Apoptosis and Bcl-2 Expression in Relation to Age, Tumor Characteristics and Prognosis in Breast Cancer

  1999cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Age as a prognostic factor in breast cancer.

  1998cited by this paper
• Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.

  1997cited by this paper
• Standardized mitotic counts in breast cancer. Evaluation of the method.

  1996cited by this paper
• Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.

  1996cited by this paper
• Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns

  1996cited by this paper
• Prognostic value of bcl-2 expression in invasive breast cancer.

  1995cited by this paper
• ErbB-2 oncoprotein overexpression in breast carcinoma: Inverse correlation with biochemically- and immunohistochemically-determined hormone receptors

  1995cited by this paper
• Apoptosis suppressing protein bcl‐2 is expressed in well‐differentiated breast carcinomas with favourable prognosis

  1995cited by this paper
• Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques

  1994cited by this paper
• Bcl-2 protein expression and long-term survival in breast cancer.

  1994cited by this paper
• Age as prognostic factor in premenopausal breast carcinoma.

  1993cited by this paper
• Immunohistochemical and Biochemical Measurement of Estrogen and Progesterone Receptors in Primary Breast Cancer Correlation of Histopathology and Prognostic Factors

  1993cited by this paper
• Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

  1992cited by this paper
• Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.

  1992cited by this paper
• Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features and with prognosis.

  1992cited by this paper
• Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro.

  1992cited by this paper
• Estrogen, Progesterone Receptors and Proliferating Activity Evaluated by Immunocytochemistry in Breast Cancer

  1991cited by this paper
• Hormone receptors as prognostic factors in female breast cancer.

  1991cited by this paper
• Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer.

  1990cited by this paper
• Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression.

  1990cited by this paper
• Correlation of steroid receptors with histologic differentiation in mammary carcinoma a singapore experience

  1985cited by this paper
• The value of morphometry to classic prognosticators in breast cancer

  1985cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• A Histopathological Study of the Breast Cancer Cases Registered at Benghazi Medical Center from 2016 to 2018

  2023cites this paper
• Prevalence and Correlates of the Estrogen and Progesterone Receptors (ER/PR), Human Epidermal Growth Factor Receptor-2 (HER-2) and P53 in Breast Cancer: a Cross-Sectional Study

  2022cites this paper
• Assessment of Breast Cancer Immunohistochemical Properties with Demographics and Pathological Features; A Retrospective Study

  2021cites this paper
• Increased expression of estrogen receptor beta in idiopathic progressive subglottic stenosis.

  2019cites this paper
• Relationship Study of The Verified Human Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization

  2019influential citation
• Expression of Estrogen and Progesterone Receptor Status in Breast Carcinoma Using Quick Score

  2018cites this paper
• [Molecular characterization of breast cancer in clinical practice].

  2016cites this paper
• Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.

  2016cites this paper
• Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample

  2016cites this paper
• The role of protein kinase PAK1 in the regulation of estrogen-independent growth of breast cancer

  2015cites this paper
• CD105 Expression on CD34-Negative Spindle-Shaped Stromal Cells of Primary Tumor Is an Unfavorable Prognostic Marker in Early Breast Cancer Patients

  2015cites this paper
• A Quality Initiative of the Program in Evidence-Based Care ( PEBC ) , Cancer Care Ontario ( CCO ) Guideline on Hormone Receptor Testing in Breast Cancer

  2014cites this paper
• Cutpoint Methods in Digital Pathology and Companion Diagnostics

  2014cites this paper
• Nuclear morphometry, apoptotic and mitotic indices, and tubular differentiation in Libyan breast cancer

  2014cites this paper
• Prognostication of Canine Mammary Carcinomas Based on Histological and Immunohistochemical Subtypes

  2014cites this paper
• Hormone receptor expression in breast cancer: postanalytical issues

  2013cites this paper
• Morphological profile and receptor status in breast carcinoma: an institutional study.

  2013cites this paper
• Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer

  2013cites this paper
• Molecular Mechanisms of Hormone Resistance of Breast Cancer

  2013cites this paper
• Proliferative Activity in Libyan Breast Cancer with Comparison to European and Central African Patients

  2013cites this paper
• Histological and immunohistochemical profiles predict lymph node status in women with low-intermediate risk endometrial cancer.

  2013cites this paper
• Systematic Review on Hormone Receptor Testing in Breast Cancer

  2012cites this paper
• Quantitative assessment and classification of tissue-based biomarker expression with color content analysis.

  2012cites this paper
• Estrogen receptor, progesterone receptor, and nuclear size features in female breast cancer in Libya: correlation with clinical features and survival.

  2012cites this paper
• Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer.

  2012cites this paper
• Application of morphometry, static DNA ploidy analysis, and steroid receptor expression in diagnosis and prognosis of Libyan breast cancer

  2012cites this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

  2010cites this paper
• American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cites this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cites this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cites this paper
• Selected Immunohistochemical Prognostic Factors in Endometrial Cancer

  2010cites this paper
• SHP2 is up‐regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis

  2008cites this paper
• Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44.

  2008cites this paper
• Survival analysis between patients with invasive ductal and invasive lobular breast cancer

  2008cites this paper
• Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma.

  2008cites this paper
• Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis

  2007cites this paper
• Recommendations for Improved Standardization of Immunohistochemistry

  2007cites this paper
• The importance of prognostic factors in premenopausal women with breast cancer.

  2007cites this paper
• Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.

  2007cites this paper
• Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index

  2006cites this paper
• Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

  2006cites this paper
• Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

  year unknowncites this paper